ex. WK 8 AssgnT6630.docx 1 .docx NURS-6630C Decision Tree Week 10 An Elderly Iranian Man with Alzheimers Disease NURS-6630C Psychopharmacologic Approaches to Treatment of Psychopathology Walden University An Eld
...
ex. WK 8 AssgnT6630.docx 1 .docx NURS-6630C Decision Tree Week 10 An Elderly Iranian Man with Alzheimers Disease NURS-6630C Psychopharmacologic Approaches to Treatment of Psychopathology Walden University An Elderly Iranian Man with Alzheimers Disease Alzheimer's disease (AD) is a neurodegenerative disorder with gradual cognitive and functional deficits and changes in behavior associated with amyloid and tau accumulation and depositions in the brain and considered the sixth most common cause of death (Apostolova, 2016). There has been substantial progress in genetics, neuroimaging, medical diagnostics, and AD staging in recent years, and the ability to visualize amyloid pathology in the living human brain is one of the most recent advances of AD (Apostolova, 2016). The recently revised diagnostic criteria for AD dementia include the use of biomarkers as a guide for the underlying pathology as supportive evidence, according to Apostolova (2016). Guidelines have been developed to ensure the responsible use of amyloid positron emission tomography (PET) and to actively explore the clinical and financial effects of amyloid PET imaging (Apostolova, 2016). Age is an associated increased risk factor, especially in those 65 and older, incidences of traumatic brain injuries, cardiovascular risk factors, and one or more apolipoprotein gene E4 alleles (APOE4) which may be inherited, although very rare with an increased probability of development of the disease (Hategan & Xiong, 2018). Also, acetylcholine, which. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]